Epygenix Therapeutics Announces First Patient Successfully Dosed in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

/in /by

Read Full Press Release Here:

https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301171444.html

Epygenix Therapeutics Announces First Patient Enrolled in Phase 2 Study for the Treatment of Dravet Syndrome With EPX-100

/in /by

Read Full Press Release Here:

https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-enrolled-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301144613.html

Epygenix Therapeutics Initiates Phase 2 Study for Dravet Syndrome With EPX-100

/in /by

Read Full Press Release Here:

https://www.prnewswire.com/news-releases/epygenix-therapeutics-initiates-phase-2-study-for-dravet-syndrome-with-epx-100-301133241.html

Epygenix Therapeutics Successfully Completes EPX-100 Phase I, Placebo-Controlled, Double-Blind, 2-Period Study and Ready to Phase 2 Studies

/in /by

Read Full Press Release Here:

https://www.prnewswire.com/news-releases/epygenix-therapeutics-successfully-completes-epx-100-phase-i-placebo-controlled-double-blind-2-period-study-and-ready-to-phase-2-studies-300993228.html

Epygenix Therapeutics Receives IND Approval of EPX-100 for the Treatment of Dravet Syndrome

/in /by

Read Full Press Release Here:

https://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-ind-approval-of-epx-100-for-the-treatment-of-dravet-syndrome-300892063.html

Epygenix Therapeutics Submits Investigational New Drug Application for EPX-100 to the U.S. FDA for the Treatment of Patients With Dravet Syndrome

/in /by

Read Full Release Here:

https://www.prnewswire.com/news-releases/epygenix-therapeutics-submits-investigational-new-drug-application-for-epx-100-to-the-us-fda-for-the-treatment-of-patients-with-dravet-syndrome-300872863.html

https://www.thestreet.com/story/14280950/1/epygenix-therapeutics-receives-us-fda-orphan-drug-designation-for-epx-300-for-the-treatment-of-patients-with-dravet-syndrome.html

/in /by

http://viewer.zmags.com/publication/614663a3#/614663a3/1

/in /by